Introduction {#sec1-1}
============

Chronic obstructive pulmonary disease (COPD) is a common disease that is preventable and could be treated and characterized by a persistent airflow limitation and respiratory symptoms due to abnormalities of airway and/or alveolar structures.\[[@ref1]\] COPD is one of the leading causes of mortality worldwide with the increasing prevalence and results in high economic and social burden.\[[@ref2]\] The rate of decline in forced expiratory volume in 1 s (FEV1) and ratio of FEV1 to forced vital capacity (FEV1/FVC) among COPD patients were reported to be more profound compared to normal population. The rate of decline in FEV1 from a study in Japan was 32 ml/year, and in the Lung Health Study, the declining was 45 ml/year.\[[@ref3]\] However, declining lung function within 1 year among Indonesian patients with COPD remains to be clarified.

The current study is intended to reveal the rate of decline in FEV1 and FEV1/FVC in COPD patients after 1 year of treatment at the National Referral Hospital for Respiratory Diseases in Indonesia. We also explored the COPD patient characteristics in each group according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the rate of FEV1 and FEV1/FVC decline in each group after 1 year of treatment. Potentially associated factors such as history of exacerbation, host factor, smoking history, and comorbidities were also described.

Materials and Methods {#sec1-2}
=====================

This cohort retrospective study was conducted in the COPD Outpatient Clinic of Persahabatan Hospital from August 2017 to October 2017. Patients were recruited by consecutive sampling. The study was granted ethical approval from the Institutional Review Board of the Faculty of Medicine Universitas Indonesia (Ethical Clearance No. 697/UN2.FI/ETIK/2017 with Protocol No. 17-07-0720). Inclusion criteria were stable COPD patients and willing to participate in the study by signing the written informed consent. The exclusion criteria were incomplete lung function test results 1 year ago, acute exacerbation of COPD, and those with radiological findings suggestive of typical pulmonary tuberculosis (TB). Patients were subject to medical history interview, physical examination, and spirometry using SPIROBANK II (Medical International Research, Rome, Italy) with the American Thoracic Society criteria test.

Obtained data were then statistically analyzed and *P* \< 0.05 was considered statistically significant. All statistical analyses were performed using Statistical Package for the Social Science software version 19.0 for Windows (Chicago, IL, USA).

Results {#sec1-3}
=======

There were 103 patients admitted to the COPD Outpatient Clinic, and 72 among them were excluded because 54 patients have no spirometry test result 1 year ago, while 18 other patients\' chest X-ray showed pulmonary TB appearance.

Most of the studied partcipants were males, and based on GOLD classification, Group D was the most common group, followed by B, A, and C groups. Individual aged below 64 years was prevalent, predominantly in Group B and D (symptomatic group) with mean age of 64.84 ± 9.63 years. The most common respiratory symptoms were productive cough followed by dyspnea. Majority of individuals were former smoker, and severe Brinkman Index (BI) was the most common among former smoker. All patients used long-acting bronchodilator, and most of patients were diagnosed as COPD at the age ≥60 years. Demographic characteristics are described in [Table 1](#T1){ref-type="table"}.

###### 

Chronic obstructive pulmonary disease individuals' characteristics of after 1 year of treatment

  Variables                                         COPD classification   Total (%)            
  ------------------------------------------------- --------------------- ----------- --- ---- -----------
  Gender                                                                                       
   Male                                             5                     10          1   14   30 (96.8)
   Female                                           0                     0           0   1    1 (3.2)
  Age                                                                                          
   \<64                                             1                     4           0   12   17 (54.8)
   ≥65                                              4                     6           1   3    14 (45.2)
  Respiratory symptoms                                                                         
   None                                             4                     0           0   0    4 (12.9)
   Cough                                            1                     10          0   0    11 (35.5)
   Dyspnea                                          0                     0           1   7    8 (25.8)
   Cough and dyspnea                                0                     0           0   8    8 (25.8)
  Smoking history                                                                              
   Nonsmoker                                        3                     0           0   0    3 (9.7)
   Former smoker                                    2                     10          1   15   28 (90.3)
  BI                                                                                           
   Never smoke                                      3                     0           0   0    3 (9.7)
   Mild                                             2                     0           0   0    2 (6.5)
   Moderate                                         0                     10          0   0    10 (32.3)
   Severe                                           0                     0           1   15   16 (51.6)
  Type of cigarette                                                                            
   Never smoker                                     3                     0           0   0    3 (9.7)
   Filter                                           2                     2           0   0    4 (12.9)
   Kretek                                           0                     8           1   12   21 (67.7)
   Mix                                              0                     0           0   3    3 (9.7)
  Comorbid                                                                                     
   None                                             5                     3           0   0    8 (25.8)
   Type 2 DM                                        0                     5           0   0    5 (16.1)
   Cardiovascular disease                           0                     2           1   15   18 (58.1)
  Education level                                                                              
   Elementary school                                2                     0           0   0    2 (6.5)
   Junior high school                               3                     3           0   0    6 (19.4)
   Senior high school                               0                     7           1   7    15 (48.4)
   University level                                 0                     0           0   8    8 (25.8)
  Working status                                                                               
   Working                                          5                     10          1   0    16 (51.6)
   Not working                                      0                     0           0   15   15 (48.4)
  BMI                                                                                          
   Underweight                                      5                     2           0   0    7 (22.6)
   Normal                                           0                     8           1   7    16 (51.6)
   Obese                                            0                     0           0   8    8 (25.8)
  History of exacerbation                                                                      
   \<1x without hospital care                       5                     10          0   0    15 (48.8)
   1x hospital care or 2x ≥ without hospital care   0                     0           1   15   16 (51.6)
  CAT score                                                                                    
   \<10                                             5                     0           1   0    6 (19.4)
   ≥10                                              0                     10          0   15   25 (80.6)
  Obstruction level                                                                            
   GOLD 1                                           5                     3           0   0    8 (25.8)
   GOLD 2                                           0                     7           1   12   20 (64.5)
   GOLD 3                                           0                     0           0   3    3 (9.7)
   GOLD 4                                           0                     0           0   0    0
  The use of LABACS                                                                            
   No                                               5                     6           0   0    11 (35.5)
   Yes                                              0                     4           1   15   20 (64.5)
  Age when diagnosed                                                                           
   \<60                                             2                     2           1   6    11 (35.5)
   ≥60                                              5                     7           1   7    20 (64.5)

BMI: Body mass index; CAT: COPD assessment test; COPD: Chronic obstructive pulmonary disease; GOLD: Global Initiative for Chronic Obstructive Lung Disease; LABA: Long-acting beta agonist; LABACS: LABA with inhaled corticosteroid; BI: Brinkman index

Next, we determined the decline in FEV1 and FEV1/FCV among COPD individuals \[[Table 2](#T2){ref-type="table"}\]. In this study, 26 individuals (83.9%) had declined FEV1 with the rate of 1-year decline of FEV1 as 121.53 ± 120 ml/year (95% CI 72.993--170.08, *P* \< 0.05). Sixteen individuals (51.6%) had decline in FEV1/FVC with the rate of 1-year decline of FEV1/FVC as 2.75 ± 0.47% (95% CI 46.07--57.798, *P* \< 0.05). The rate of decline in FEV1 and FEV1/FVC in COPD patient in Group A, B, C, and D are described in [Table 3](#T3){ref-type="table"}.

###### 

Rate of decline in forced expiratory volume in 1 s and forced expiratory volume in 1 s/forced vital capacity

  FEV1 and FEV1/FVC        Mean            Rate of decline   95% CI          *P*
  ------------------------ --------------- ----------------- --------------- --------
  FEV1 1 year before       1238±468        121.53±120        72.993-170.08   \<0.05
  FEV1 after 1 year        1116.9±478                                        
  FEV1/FVC 1 year before   54.67±11.05     2.75±0.47         46.07-57.798    \<0.05
  FEV1/FVC after 1 year    51.923±11.026                                     

FEV1: Forced expiratory volume in 1 s; FVC: Forced vital capacity; CI: Confidence interval

###### 

Rate of decline in forced expiratory volume in 1 s and forced expiratory volume in 1 s/forced vital capacity in chronic obstructive pulmonary disease patient Group A, B, C, and D

  Rate decline in FEV1 and FEV1/FVC   A      B      C    D
  ----------------------------------- ------ ------ ---- -----
  FEV1 (ml/year)                      72.5   85     60   110
  FEV1/FVC (percentage/year)          2.9    3.29   1    2

COPD: Chronic obstructive pulmonary diseas; FEV1: Forced expiratory volume in 1 s; FVC: Forced vital capacity

In this study, however, there were no statistically significant association between gender, age, BMI, symptom-based COPD group, risk-based COPD group, comorbidity, respiratory symptoms, BI, level of education, the use of long-acting beta agonist with inhaled corticosteroid (LABACS), age when COPD diagnosis, history of smoking, history of exacerbation, COPD assessment test (CAT) score, and obstruction severity as appear on FEV1 and FEV1/FVC \[[Table 4](#T4){ref-type="table"}\].

###### 

Factors associated with rate of decline in forced expiratory volume in 1 s

  Variables                                                FEV1 decline   Total   *P*   
  -------------------------------------------------------- -------------- ------- ----- -------
  Gender                                                                                
   Male                                                    25             5       30    0.389
   Female                                                  1              0       1     
  Age                                                                                   
   \<64                                                    13             4       17    0.23
   ≥65                                                     13             1       14    
  BMI                                                                                   
   Underweight                                             6              1       7     0.68
   Normal obese                                            20             4       24    
  Risk-based group                                                                      
   A-B (low risk)                                          14             1       15    0.18
   C-D (high risk)                                         12             4       16    
  Symptom-based group                                                                   
   A-C (less symptoms)                                     5              1       6     0.687
   B-D (more symptoms)                                     21             4       25    
  Comorbid                                                                              
   Yes                                                     19             4       23    0.615
   No                                                      7              1       8     
  Respiratory symptoms                                                                  
   Yes                                                     23             4       27    0.525
   No                                                      3              1       4     
  BI                                                                                    
   Mild-moderate                                           12             0       12    0.089
   Severe                                                  12             4       16    
  Level of education                                                                    
   Low-middle                                              7              1       8     0.615
   High                                                    19             4       23    
  The use of LABACS                                                                     
   Yes                                                     10             1       11    0.405
   No                                                      16             4       20    
  Age when diagnosis                                                                    
   \<60                                                    10             1       11    0.405
   ≥60                                                     16             4       20    
  History of smoking                                                                    
   Nonsmoker                                               2              1       3     0.42
   Former smoker                                           24             4       28    
  History of exacerbation                                                               
   \<1x without hospital care                              14             1       15    0.186
   1x with hospital care, or 2x \> without hospital care   12             4       16    
  CAT score                                                                             
   \<10                                                    5              1       6     0.687
   ≥10                                                     21             4       25    
  GOLD                                                                                  
   1-2                                                     23             5       28    0.578
   3-4                                                     3              0       3     

CAT: COPD assessment test; COPD: Chronic obstructive pulmonary disease; FEV1: Forced expiratory volume in 1 s; GOLD: Global Initiative for Chronic Obstructive Lung Disease; LABACS: LABA with inhaled corticosteroid; LABA: Long acting beta agonist; BI: Brinkman index

Discussion {#sec1-4}
==========

COPD is characterized by a progressive deteriorating airway obstruction, and preserving lung function was one of the main targets of treatment. The current study observed a reduced lung function, i.e., FEV1 and FEV1/FVC, within 1 year among Indonesian patients with COPD.

This study identified a marked decline in FEV1 which might be associated with the patients characteristic, such as male, mean of age 64.84 ± 9.63 years, former smoker with severe BI, Kretek cigarette, cardiovascular disease as comorbid, history of exacerbation leading to hospital, CAT score \>10, and age during COPD diagnosis ≥60 years.

The rate of decline in FEV1 in Group A was 72.5 ml/year, Group B 85 ml/year, Group C 60 ml/year, and Group D 110 ml/year. Higher rate of decline in FEV1 was in Group D and B (symptomatic group) followed by A and C (less symptomatic group). The rate of decline in FEV1/FVC in Group A was 2.9%, Group B 3.29%, Group C 1%, and Group D 2%; this suggests that most common decline in FEV1/FVC was in Group B and A (low-risk group) compared to D and C (high-risk group).

Result in this study was different with the study performed by Kanazawa *et al*. in 55 COPD patients with marked decline in FEV1 in Group B (59.7 ml/year) and C (54.0 ml/year).\[[@ref4]\] Kim *et al*. showed decline of FEV1 was common in Group A (34.4 ± 7.9 ml/year) followed by Group B (26.2 ± 9.4 ml/year), Group D (24.0 ± 8.7 ml/year), and Group C (22.7 ± 16.0 ml/year).\[[@ref5]\]

Studi by Chen *et al*. found that a decline in FEV1 was 129 ml in low-risk group of COPD and this is 30 ml different higher compared to decline in high-risk group.\[[@ref6]\] A prospective cohort study, the Korean Obstructive Lung Disease, by Kim *et al*. showed that a decline in FEV1 was faster in low-risk group of COPD compared to the high-risk group (31.0 ± 6.1 ml/year vs. 23.6 ± 7.7 ml/year), although it was not statistically significant (*P* = 0.44).\[[@ref5]\] They also found that less symptomatic COPD patients had a lesser decline in FEV1 compared to more symptomatic patients (32.3 ± 7.2 ml/year vs. 25.0 ± 6.5 ml/year).\[[@ref5]\]

We did not find significant association between obstruction variable in lung function with individual characteristics. This result is different with previous study. In one study by Watson *et al*., decline in FEV1 was associated with respiratory symptoms only in male individuals.\[[@ref7]\] Study by Han *et al*. found that a decline in FEV1 was important predictor of the disease state.\[[@ref8]\]

We did not find a significant association between the use of LABACS and declined lung function among COPD patients. A multicenter study, ISPIRE, performed for a 2-year period showed no significant association between FEV1 in both salmeterol/fluticason propionat group and tiotropium group.\[[@ref9]\]

BMI was not associated with the decline in FEV1 in our cohort, and this is consistent with previous cross-sectional study by Kakarla *et al*. who demonstrated no significant association between FEV1 and 6 min walk test (6MWT), both in lower BMI and high BMI group.\[[@ref10]\]

Patients with T2DM in the current study were only 5 patients, and we did not observe an association between comorbidity and decline in FEV1 and in FEV1/FCV. This is different with study by Kwon *et al*. who observed a significant association between T2DM and decline in both FEV1 and FVC.\[[@ref11]\]

Patients with respiratory symptoms had more profound decline in lung function although this did not reache statistical threshold. This is consistent with previous study by Watson *et al*. who demonstrated that decline FEV1 within 1 year was not significantly associated with respiratory symptoms both in men and women.\[[@ref7]\]

The study limitation was a relatively small sample because the study was performed in a short term. Further study involving larger sample size is required to identify potential factors that might contribute in the reduced lung function among Indonesian patients with COPD.

Conclusions {#sec1-5}
===========

Taken together, a marked proportion of COPD patients suffered a declining FEV1 and FEV1/FVC within 1 year, and this represents unachieved therapeutic target. There were no significant associations between sex, age, respiratory complaints, smoking history, BI, type of cigarette, comorbid, educational level, diagnosed age, body mass index, symptoms-based COPD classification, and risk-based COPD classification, with the rate of decline in FEV1 and FEV1/FVC.
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